NIAID Testing Remdesivir Plus MS Drug for COVID-19 NIAID Testing Remdesivir Plus MS Drug for COVID-19

The ACTT-3 randomized controlled trial is testing the safety and efficacy remdesivir in combination with the immunomodulator interferon beta-1a in hospitalized COVID-19 patients.Medscape Medical News
Source: Medscape Emergency Medicine Headlines - Category: Emergency Medicine Tags: Neurology & Neurosurgery News Source Type: news